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G. William Dec, MD,y Eloisa Arbustini, MDzC ardiomyopathy is deﬁned as a myocardialdisorder of unknown origin in which theheart muscle is structurally and function-
ally abnormal. Little has changed from the original
deﬁnition offered by Goodwin and Oakley in 1972,
when they classiﬁed cardiomyopathies as dilated,
hypertrophic, and restrictive (or obliterative) (1).
Subsequently, the “myocardial disease of unknown
origin” concept was adopted in the 1976 World
Health Organization classiﬁcation (2). This deﬁnition
was substantially unchanged until the American
Heart Association (3) in 2006 and the European Soci-
ety of Cardiology (1) in 2008 formally recognized
genetic and nongenetic (or acquired and mixed)
forms.
Grouping cardiomyopathy into morpho-functional
phenotypes, such as dilated cardiomyopathy (DCM),
hypertrophic cardiomyopathy, restrictive cardiomy-
opathy, and arrhythmogenic right ventricular car-
diomyopathy, has been key for the extraordinary
progress in understanding the etiologic basis, both
genetic and nongenetic, of cardiomyopathies. In
day-to-day clinical practice, patients are managed
exclusively according to their morpho-functional
phenotype. The revelation that most cardiomyopa-
thies are familial diseases has spurred identiﬁca-
tion of disease-causing genes, starting with linkage
analysis in large families (4), and subsequently
exploiting genome-wide associations (5) and next-*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yCardiology Division, Massachusetts General Hospital, Boston,
Massachusetts; and the zPoliclinico San Matteo, Pavia, Italy. Both authors
have reported that they have no relationships relevant to the contents of
this paper to disclose.generation sequencing up to exome and whole-
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Genetic testing is fast becoming part of the diag-
nostic evaluation of cardiomyopathies (6). The cur-
rent problem: interpreting the role of mutations that
are identiﬁed when screening multigene panels,
especially in cardiomyopathies that do not exhibit
clinical markers associated with defects of speciﬁc
genes. Cardiomyopathies are genetically heteroge-
neous diseases; each subgroup of cardiomyopathy
can be causally linked to different genes whose
effects produce a similar phenotype. Consequently,
gene-speciﬁc treatments are not available for car-
diomyopathic disorders, with a few exceptions for
phenocopies; these include storage diseases with
cardiac involvement in which disease-speciﬁc inter-
vention has become available (7). Although our
knowledge of the etiology of cardiomyopathies has
increased exponentially, therapeutic strategies still
remain based on the morpho-functional phenotype.
There is an emerging clinical need for generating
large subgroups of cardiomyopathies with an
identical etiological basis (caused by mutations of
the same genes or the same speciﬁc mutations) to
develop targeted treatments. The paradigmatic
example on how the molecular and genetic mecha-
nisms of diseases affect therapeutic innovation comes
from the growing array of targeted treatments used in
cancer management that have dramatically altered
clinical outcomes. In cardiovascular medicine, car-
diomyopathies may prove to be among the most
eligible disorders amenable to targeted intervention.
In 2013, the World Heart Foundation endorsed a
comprehensive classiﬁcation system for cardiomy-
opathies called MOGE(S) (8), which maintained the
morpho-functional identiﬁcation but prominently
addressed the disease’s genetic basis. Similar to the
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13253 major nosologic descriptors of TNM (tumor; nodes;
metastasis) cancer staging, the MOGE(S) classiﬁcation
facilitates a comprehensive disease description in
5 speciﬁc categories.
 M stands for the morpho-functional phenotype of
the cardiomyopathy, presenting as hypertrophic,
dilated, restrictive, and arrhythmogenic pheno-
types, and includes overlapping combinations.
 O denotes organ involvement. The complete in-
formation about additional extracardiac involve-
ment allows easy recognition of syndromic
patterns.
 G, for genetic transmission, is presented as auto-
somal dominant, autosomal recessive, X-linked, or
matrilineal; nongenetic (0) or unknown/unproven
origin can also be presented.
 E, for etiology, is presented as G for genetic disease
(followed by the disease gene and mutation in red
if pathologic, yellow if genetic variant is of un-
known signiﬁcance, and green for a single nucle-
otide polymorphism with some possible functional
effects).
 S represents disease stage, including American
College of Cardiology/American Heart Association
stages (A to D) followed by New York Heart Asso-
ciation (NYHA) functional classes (I to IV).
This nomenclature allows a more coherent and
homogeneous description of etiologically diverse
diseases (Figure 1).
CAN MOGE(S) CONTRIBUTE TO
PROGNOSTIC STRATIFICATION?
In this issue of the Journal, Hazebroek et al. (9)
applied the MOGE(S) classiﬁcation and assessed its
prognostic value in a cohort of 213 patients with
unexplained DCM. The clinical diagnostic protocolThe panels show 2 different pathological sections from an explanted heart: photo-
micrographs of a patient with familial dilated cardiomyopathy (DCM) and a patho-
logical mutation in the LMMA gene. MOGE(S) describes the phenotype (D with
conduction defect AVB); the heart (H) as unique organ involvement; the genetic (G),
autosomal dominant (AD) transmission pattern; the etiology, genetic associated with
an LMNA pathological (red) mutation; and stage D with New York Heart Association
functional class IV.
SEE PAGE 1313included detailed personal and family histories,
physical examination, electrocardiogram, echocardi-
ography, and right ventricular endomyocardial
biopsy (EMB) for systematic determination of the
deoxyribonucleic acid/ribonucleic acid proﬁles of 6
cardiotropic viruses. Genetic evaluation, including
pedigree analysis and disease gene screening to
detect pathogenic mutations, was also performed.
The primary endpoints were death, heart trans-
plantation, or life-threatening arrhythmias; the sec-
ondary endpoint focused on left ventricular reverse
remodeling (LVRR) at 12 months.
The authors identiﬁed several key clinical ﬁndings
from their analysis (9). At least 1 speciﬁc diseaseetiology was documented in 73% of the cases; more
importantly, 23% of patients had >1 potential patho-
genic etiology. Organ involvement outside the heart
was relatively common (16%). Pathogenic mutations
were relatively uncommon (8%) compared with other
reported series and were understandably more
commonly observed in patients with familial DCM
(17%) than nonfamilial DCM (4%). Conversely, LVRR
was more frequently observed in nongenetic familial
DCM (40% vs. 25%). Predictors of adverse clinical
outcome were higher NYHA functional class, organ
involvement, and lower baseline left ventricular
ejection fraction. Importantly, genetic/familial DCM
alone had no prognostic signiﬁcance, but when
accompanied by etiological/environmental factors
(i.e., signiﬁcant viral load, rhythm disturbances,
toxic triggers), a worse outcome was observed. The
authors also developed a MOGE(S) scoring system
ranging from 0 to 4, assigning 1 point for each attri-
bute and/or gene–environment interaction (i.e.,
noncardiac organ involvement, gene plus environ-
mental factors, NYHA functional class). A substan-
tially worse outcome was observed for patients with
MOGE(S) score $2, validating its clinical utility in a
predictive model.
The strengths of the study by Hazebroek et al. (9)
include the detailed systematic clinical, genetic, and
pathological examinations performed in each patient;
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1326the use of hard endpoints, including mortality and
transplantation; assessment of LVRR over 1 year of
complete follow-up; and the specialized expertise
of a major cardiomyopathy center with established
protocols for diagnosing genetic and nongenetic
forms of DCM. The authors appropriately listed
several of the study’s limitations, including the
single-center experience, the potential for selection
bias (because not all patients underwent all diag-
nostic investigations), use of right ventricular (not
biventricular) EMB with a lower rate of pathological
detection of focal or multifocal myocardial pro-
cesses, and the limited number of viral genomes
assayed in the EMB. Furthermore, the study detec-
ted a surprisingly low percentage of pathogenetic
mutations (overall 8%). In addition, cardiac mag-
netic resonance data, which are increasingly im-
portant in evaluating new DCM, were not provided;
the study also lacked data on pharmacological
therapy and its effects on left ventricular remodel-
ing. Finally, due to the small sample size and the
relatively low event rates, the study had insufﬁcient
power to perform multivariable modeling to test for
independent predictors of outcome. Nonetheless,
this novel study supports the idea of applying the
MOGE(S) classiﬁcation to assess clinical prognosis
and risk stratiﬁcation in patients with DCM.
Although the scoring system proposed by Hazebroek
et al. requires validation in a larger series, the study
afﬁrmed the need for more precise risk stratiﬁcationthat includes the speciﬁc etiologic basis or bases of
disease.
This study (9) helps validate the important concept
that a combination of etiologic factors, speciﬁcally
genetic and environmental factors, might jointly
participate in DCM pathogenesis. Although this is not
a novel concept, the study provides insights into how
to move forward with the difﬁcult task of integrating
genetics and a systematic search for contributory
environmental factors.
The MOGE(S) classiﬁcation of cardiomyopathies
has been attracting clinical attention because of its
ability to integrate comprehensive data into a single
descriptor. Its importance for prognostic risk stratiﬁ-
cation could add considerably to its original descrip-
tive and diagnostic attributes. Further studies in
larger and more diverse cardiomyopathy cohorts will
be necessary to validate and extend the work by
Hazebroek et al. (9). Nonetheless, these intriguing
ﬁndings suggest that more precise disease staging
could pave the way for improving the prognosis in
DCM through disease-speciﬁc therapeutic strategies.
Perhaps it is time for the MOGE(S) classiﬁcation to
enter into more routine clinical use.
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